Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.21.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Operating expenses:    
Research and development $ 12,382 $ 9,509
General and administrative 5,236 4,418
Total operating expenses 17,618 13,927
Loss from operations (17,618) (13,927)
Interest income 67 839
Net loss (17,551) (13,088)
Other comprehensive loss:    
Unrealized loss on marketable securities (14) (210)
Total other comprehensive loss (14) (210)
Comprehensive loss $ (17,565) $ (13,298)
Basic and diluted net loss per common share $ (0.25) $ (0.19)
Weighted average common shares outstanding used to calculate basic and diluted net loss per common share 68,946,092 68,882,459